Overzicht
Wijziging aandelenprijs
24u
Huidig
Min
43.3
Max
45.08
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +46.09% upside |
Rigel Pharmaceuticals Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
12 nov 2026, 21:07 UTC
Rigel Pharmaceuticals, Inc. shares advanced during Thursday's session, despite earlier pulling back, following the release of disappointing earnings for the year ending September 2026.
Lezen
10 nov 2026, 21:07 UTC
Rigel Pharmaceuticals CEO Raul Rodriguez will present at the Jefferies Global Healthcare Conference on November 17, 2026, discussing therapies for hematologic disorders and cancer.
Lezen
9 nov 2026, 21:03 UTC
Rigel Pharmaceuticals, Inc. shares rose sharply after Citigroup maintained a Buy rating and raised its price target to $86 from $83, amid high trading volume.
Lezen
6 nov 2026, 21:02 UTC
Rigel Pharmaceuticals reported Q3 EPS of $0.65, below the $0.96 estimate, and adjusted FY 2026 sales guidance to $290M-$295M, missing expectations.
Lezen
5 nov 2026, 23:56 UTC
Rigel Pharmaceuticals reports Q3 2026 net income of $13.2 million, missing expectations, and revises full-year revenue guidance down to $290-$295 million.
Lezen
4 nov 2026, 21:07 UTC
Rigel Pharmaceuticals will present updated data from its Phase 1b clinical study of R289 at the American Society of Hematology Annual Meeting on December 12, 2026.
Lezen
3 nov 2026, 21:07 UTC
Rigel Pharmaceuticals, Inc. shares are declining, continuing a trend of weaker performance over the past three sessions amid overall market volatility.
Lezen
2 nov 2026, 20:56 UTC
Rigel Pharmaceuticals, Inc. shares fell over one percent after pulling back from an earlier session high, though they remain above the 20-day moving average.
Lezen
30 okt 2026, 23:06 UTC
Rigel Pharmaceuticals, Inc. shares declined sharply during after-market hours, reaching their lowest point since Friday's close amid a broader market decline.
Lezen
29 okt 2026, 21:02 UTC
Rigel Pharmaceuticals, Inc. is declining in after-market trading, falling significantly since Thursday's close.
Lezen
22 okt 2026, 20:07 UTC
Rigel Pharmaceuticals Inc's shares are slightly higher, maintaining a position above the 20-day moving average amid broader market gains.
Lezen
21 okt 2026, 20:07 UTC
Rigel Pharmaceuticals Inc. shares advanced on Wednesday, continuing a trend of higher daily finishes and remaining above their 20-day moving average.
Lezen
20 okt 2026, 20:08 UTC
Rigel Pharmaceuticals Inc will present pooled efficacy and safety data from two clinical trials of GAVRETO® at the European Society For Medical Oncology Congress on October 25, 2026.
Lezen
19 okt 2026, 20:07 UTC
Rigel Pharmaceuticals reported positive GAVRETO data at ESMO, showing a 53% overall response rate in RET fusion-positive solid tumors, with HC Wainwright reiterating a Buy rating.
Lezen
15 okt 2026, 19:56 UTC
Rigel Pharmaceuticals Inc is trading higher, rebounding after three sessions of declines, supported by strength in the broader biotechnology sector.
Lezen
14 okt 2026, 21:31 UTC
Rigel Pharmaceuticals Inc is experiencing a significant decline in after-market trading, continuing a trend of four consecutive sessions finishing lower.
Lezen
13 okt 2026, 19:16 UTC
Rigel Pharmaceuticals Inc shares fell, continuing a notable decline since Monday's close amid unusual activity, with prices around the middle of their one-month range.
Lezen
8 okt 2026, 20:01 UTC
Rigel Pharmaceuticals Inc is trading higher, reaching a peak return after initial declines, currently above its 20-day moving average and near the upper end of its one-month range.
Lezen
7 okt 2026, 20:01 UTC
Rigel Pharmaceuticals Inc is seeing a higher trading session today, marked by unusually high share volume, diverging from its recent upward trend since Tuesday.
Lezen
6 okt 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares fell sharply, continuing a downward trend since Monday, with the price remaining well below its 20-day moving average.
Lezen
5 okt 2026, 21:01 UTC
Rigel Pharmaceuticals Inc is trading lower in after-market hours, extending a decline that started at Monday's close amid a notably quiet session.
Lezen
1 okt 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares fell sharply, closing significantly lower amid consistent pressure and a four-session losing streak below the 20-day moving average.
Lezen
24 sep 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares fell, continuing a downward trend since Wednesday, despite a midday recovery, remaining below their opening level.
Lezen
23 sep 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares fell sharply amid a declining broader market, reaching a low of nearly 3.75% below Tuesday's close before a slight recovery.
Lezen
18 sep 2026, 20:02 UTC
Rigel Pharmaceuticals Inc is advancing today with unusually high trading activity, breaking from a recent trend of higher daily closes since Thursday.
Lezen
15 sep 2026, 20:02 UTC
Rigel Pharmaceuticals is trading lower as the NY Empire State Manufacturing Index fell sharply, raising concerns about economic contraction in New York's manufacturing sector.
Lezen
11 sep 2026, 19:46 UTC
Rigel Pharmaceuticals is higher today, influenced by CPI data and speculation about potential Federal Reserve interest rate hikes. The stock remains near its one-month trading range.
Lezen
10 sep 2026, 23:21 UTC
Rigel Pharmaceuticals Inc is rising in after-market trading, reversing a three-session decline. No specific news was identified to explain this price action.
Lezen
8 sep 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares are lower today, continuing a decline since Friday. The stock saw notable volatility but remains above its 20-day moving average.
Lezen
1 sep 2026, 20:08 UTC
Rigel Pharmaceuticals Inc shares are higher today, reflecting strong market performance and robust momentum above the 20-day moving average. No specific news was identified.
Lezen
Peer Vergelijking
Prijswijziging
Rigel Pharmaceuticals Inc Prognose
Koersdoel
By TipRanks
12 Maanden Prognose
Gemiddelde 66.75 USD 46.09%
Hoogste 86 USD
Laagste 47 USD
Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rigel Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.
Beoordelingsconsensus
By TipRanks
Buy
4 ratings
2
Buy
2
Hold
0
Sell
Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Rigel Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.
Financieel
$